

Peer-reviewed analysis of EchoSolv HF demonstrates potential of technology to improve precision of heart failure diagnosis

- Peer-reviewed analysis of EIQ's AI-based algorithm, EchoSolv HF, published in the Journal of the American College of Cardiology (JACC) Advances, a leading medical research journal
- Research paper showed the AI model, which forms the basis of EchoSolv HF generated output, is consistent with improved detection rates for left ventricular dysfunction
- Left ventricular dysfunction is a cause of reduced blood flow and potentially heart failure
- Report concluded that EchoSolv HF has the potential to contribute to improve the precision of physician diagnosis and contribute to improved health outcomes
- Results provide strong platform for follow-up analysis on specific independent datasets to further strengthen the clinical validation of the technology
- More broadly, CEO Dustin Haines to present recent progress at the AI & Technology Virtual Investor Conference hosted by VirtualInvestorConferences.com, on July 10, 2025
- Virtual Investor Conferences (VIC) is a leading conference series that provides an interactive forum for OTC-listed and other publicly traded companies to present directly to investors

Sydney: AI and Medical Technology company Echo IQ ("the Company" or "Echo IQ") (ASX: EIQ, OTCQB: ECHQF) is pleased to advise the results of a peer-reviewed analysis of the artificial intelligence ("AI") technology underpinning EchoSolv HF, the Company's clinical decision support solution for heart failure, which was recently published in JACC Advances - a Journal of the American College of Cardiology publication.

The study paper, titled "Artificial Intelligence for Detection of Prognostically Significant Left Ventricular Dysfunction From Echocardiography"ⁱ, outlined the training and test methodology of the AI-based model (AI-LVD) for the detection of heart failure, and examined the operational characteristics of the model in its ability to identify increasing levels of prognostically important left ventricular (LV) dysfunction.

LV dysfunction refers to a condition where the left ventricle, the heart's main pumping chamber, is unable to contract or relax effectively, leading to reduced blood flow and potentially heart failure.

The results verified that when applied to a statistically significant cohort of echocardiographic measurement data, the LV AI-based model can reliably identify abnormalities of LV dysfunction in patients at high risk of developing HF and, most importantly, at risk of premature mortality.

Using the same echocardiographic data, the AI-based software also identified worsening LV dysfunction for each category of LVEF¹ (left ventricular ejection fraction) – the benchmark for prognostically important levels of left ventricular systolic dysfunction – even when key parameters were missing.

The paper concluded that the AI-LVD model shows promise to assist physicians in the timely and accurate diagnosis in each LVEF category of heart failure. If used optimally during echocardiographic interpretation, it

has the potential to improve the precision of physician diagnosis and the application of guideline-directed medical therapy to achieve improved health outcomes.

Further clinical validation of the AI-LVD algorithm will involve application of the technology to new independent datasets comprising clinical Heart Failure diagnoses and related hospitalizations. Follow-up analysis will help determine the potential clinical utility of the AI-LVD to identify prognostically relevant LV dysfunction, assist in clinical HF diagnosis, and help predict future HF hospitalization events.

The peer-reviewed analysis follows the formal commencement of a clinical validation study for EchoSolv HF in collaboration with the Mayo Clinic Platform, marking the final regulatory requirement prior to a formal FDA submission for the technology which is scheduled in the coming months (refer ASX Announcement 1 July 2025).

¹EF is ejection fraction - the percentage of blood pumped out of the left ventricle with each heartbeat and a key measurement used to assess heart function and potential heart failure.

Presentation at the AI & Technology Virtual Investor Conference, 10 July:

The Company advises that CEO, Mr Dustin Haines will also be presenting recent company progress at AI & Technology Virtual Investor Conference hosted by VirtualInvestorConferences.com, on 10 July 2025. The conference is part of the Company's OTCQB listing and marks access to the US' preeminent online investor conference series.

The presentation will be live and part of an interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available following the event.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Details of the event are below:

Date: 10 July 2025

Time: 10:00am EDT

Registration link: <https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5015990/echoiq-limited-otcqb-echqf-asx-eiq>

Management commentary:

Chief Executive Officer, Mr Dustin Haines said: *"The peer-reviewed study paper further underscores the potential of the AI-based algorithm that forms the basis of the EchoSolv HF product offering to assist in achieving improved detection rates of abnormalities associated with heart failure."*

"The JACC paper adds to the body of research indicating that the application of EchoSolv HF can assist physicians to optimise heart failure diagnosis in a clinical setting. This in turn provides a strong basis for ongoing analysis of the technology on existing datasets to complement our clinical development pathway."

"This publication leaves the Company in very good standing and will serve to highlight the potential of our technology to a broad industry audience. To complement this, I look forward to presenting at the OTC's AI and technology conference in the coming days, to reiterate the Company's investment case to investors."

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.

ⁱ <https://www.jacc.org/doi/10.1016/j.jacadv.2025.101891>